This is a working overview of GIP receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-31 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
25 Jan&1 Sep) mimicking neurons' communication, is reported. 9 November IBM unveils its 433-qubit 'Osprey' quantum processor, the successor to its Eagle system. A study shows that 50+ aged users of the dietary program SNAP "had about 2 fewer years of cognitive aging over a 10-year period compared with non-users" despite it having nearly no conditions for the sustainability and healthiness of the food products purchased with the coupons (or coupon-credits). 10 November A study describes how one may eventually be able to detect (distinguish) wormholes, suggesting they may have never been observed because they appear very similar to black holes. Notable software developments: After domain seizures of Z-Library by copyright law enforcement and moves toward dark web and IPFS technologies by its content providers, the open source shadow library UI Anna's Archive – which also provides access to a full copy of Z-Library content and scientific articles – is established by a team of archivists, essentially providing the largest human book and literature library. News outlets report about the development of a post-editing model using GPT-3 that improves machine translations after identification of current translation problems (8 Nov/25 Oct). The largest global inventory and interactive map of greenhouse gas emission sources is released by Climate TRACE (9 Nov).
== Cell imaging == Chemical tags have been tailored for imaging technologies more so than fluorescent proteins because chemical tags can localize photosensitizers closer to the target proteins. Proteins can then be labeled and detected with imaging such as super-resolution microscopy, Ca2+-imaging, pH sensing, hydrogen peroxide detection, chromophore assisted light inactivation, and multi-photon light microscopy. In vivo imaging studies in live animals have been performed for the first time with the use of a monomeric protein derived from the bacterial haloalkane dehalogenase known as the Halo-tag. The Halo-tag covalently links to its ligand and allows for better expression of soluble proteins.
The third and final mission's crew, Skylab 4, set a human endurance record (at the time) with 84 days in orbit when the mission ended on February 8, 1974. Skylab stayed in orbit another five years before reentering the Earth's atmosphere over the Indian Ocean and Western Australia on July 11, 1979. Salyut 4 broke Skylab's occupation record at 92 days. Salyut 6 and Salyut 7 were second-generation stations designed for long duration, and were occupied for 683 and 816 days. Salyut 7 improved upon earlier designs by allowing long-duration crewed missions and more complex experiments. These stations, with their expanded crew capacity and amenities for long term stay, carrying electric stoves, a refrigerator, and constant hot water.
Sources: en.wikipedia.org
Forcipulatida (6 families, 63 genera, 269 species) Species in this order have distinctive pedicellariae, consisting of a short stalk with forceps-like tips. and tube feet with flat-tipped suckers usually arranged in four rows. The order includes well-known species from temperate and cold-water regions, ranging from intertidal to abyssal zones. Notomyotida (1 family, 8 genera, 75 species) These starfish are deep-sea dwelling and have particularly flexible arms with distinctive lines of musculature along the sides of the dorsal region. In some species, the tube feet lack suckers.
=== Casting === Brec Bassinger was cast as Courtney Whitmore / Stargirl in September 2018. Johns called the casting of Stargirl a difficult process, auditioning hundreds of actresses for the role. On why Bassinger was perfect for the role, Johns said: "Immediately... I knew she was Courtney. She has the humor, she has the enthusiasm, the energy, the innate optimism, and Brec really embodies who Stargirl is". The following roles were cast in November: Anjelika Washington as Beth Chapel / Doctor Mid-Nite, Yvette Monreal as Yolanda Montez / Wildcat, and Christopher James Baker as Henry King / Brainwave. In January 2019, Luke Wilson was cast as Pat Dugan / S.T.R.I.P.E. Amy Smart joined the cast as Barbara Whitmore in February, along with Neil Jackson as Jordan Mahkent / Icicle, Trae Romano as Mike Dugan, Hunter Sansone as Cameron, and Cameron Gellman as Rick Tyler / Hourman. Also Jake Austin Walker was cast as Henry King Jr. and Meg DeLacy cast as Cindy Burman. The following members of the Justice Society of America were cast in December 2018: Joel McHale as Sylvester Pemberton / Starman, Lou Ferrigno Jr. as Rex Tyler / Hourman, Brian Stapf as Ted Grant / Wildcat, and Henry Thomas as Charles McNider / Doctor Mid-Nite. As well, Joy Osmanski was cast as Paula Brooks / Tigress, Neil Hopkins was cast as Lawrence "Crusher" Crock / Sportsmaster, and Nelson Lee was cast as Dr. Ito / Dragon King, members of the Injustice Society. In April 2019, Hina Khan was cast as Anaya Bowin.
She was in Idris, hiding from her shame when she heard the news that her sister Barbara had died of demon poison. She collapsed upon hearing it and her mother and father traveled via Portal to be with her while they grieved, though she returned to London after the quarantine had been lifted and attended an Enclave meeting in the London Institute with them to discuss the full of what had happened between the attacks that had killed Barbara and a few others. Charles Fairchild — an ambitious young man hoping to succeed his mother as Consul, and Matthew's older brother. He is self-conscious about his reputation and is in a secret relationship with Alastair Carstairs for most of the book.
While the building could accommodate a staff of thirty researchers, twenty-five technicians and forty to fifty students, there was only a fraction of that number, and morale was low. Florey retained Jean Orr-Ewing and Margaret Campbell-Renton, who had been working with Dreyer, and brought Kent with him. Pullinger joined them soon after as demonstrator of pathology. Florey and Pullinger restructured the pathology course. He hired Margaret Jennings as a gastroenterologist in October 1936, and she worked with him on his studies of mucus secretion. She became Florey's mistress in 1940; their affair was a poorly-kept secret. He appointed P. J. Smart as the office administrator, and she remained in the role until she retired in 1976. He attracted Rhodes Scholars such as Australian Brian Maegraith and Americans Robert H. Ebert and Leslie Epstein to the Sir William Dunn School of Pathology; other doctoral students included Peter Medawar, Gordon Sanders and Jean Taylor. Arthur Duncan Gardner headed the MRC's Standards Laboratory, which was located on the premises, and Gardner expected that his unit would have to move out, but Florey moved to keep him, as he needed a good bacteriologist. He arranged for Gardner to become head of his bacteriological section, with the title of reader of bacteriology in 1936. The Standards Laboratory eventually moved to the MRC's laboratories at Colindale, but not until 1946. Florey also wanted a biochemist on his staff, but this proved difficult. He acquired the services of E. A. H.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.